Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/133898
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | McMillan, M. | - |
dc.contributor.author | Marshall, H.S. | - |
dc.contributor.author | Richmond, P. | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Expert Review of Vaccines, 2022; 21(1):103-114 | - |
dc.identifier.issn | 1476-0584 | - |
dc.identifier.issn | 1744-8395 | - |
dc.identifier.uri | https://hdl.handle.net/2440/133898 | - |
dc.description | Published online: 29 Nov 2021 | - |
dc.description.abstract | Introduction: Vaccination is the most effective method of protecting people from invasive meningococcal disease (IMD). Of all the capsular groups, B is the most common cause of invasive meningococcal disease in many parts of the world. Despite this, adolescent meningococcal B vaccine programs have not been implemented globally, partly due to the lack of evidence for herd immunity afforded by meningococcal B vaccines. Areas Covered: This review aims to synthesise the available evidence on recombinant 4CMenB vaccines' ability to reduce pharyngeal carriage and therefore provide indirect (herd) immunity against IMD. Expert Opinion: There is some evidence that the 4CMenB vaccine may induce cross-protection against non-B carriage of meningococci. However, the overall body of evidence does not support a clinically significant reduction in carriage of disease-associated or group B meningococci following 4CMenB vaccination. No additional cost-benefit from herd immunity effects should be included when modelling the cost-effectiveness of 4CMenB vaccine programs against group B IMD. 4CMenB immunisation programs should focus on direct (individual) protection for groups at greatest risk of meningococcal disease. Future meningococcal B and combination vaccines being developed should consider the impact of the vaccine on carriage as part of their clinical evaluation. | - |
dc.description.statementofresponsibility | Mark McMillan, Helen S Marshall and Peter Richmond | - |
dc.language.iso | en | - |
dc.publisher | Taylor & Francis | - |
dc.rights | © 2021 Informa UK Limited, trading as Taylor & Francis Group | - |
dc.source.uri | http://dx.doi.org/10.1080/14760584.2022.2003708 | - |
dc.subject | Bexsero; carriage; herd protection; herd immunity; meningococcal; Neisseria meningitidis; 4cmenb | - |
dc.title | 4CMenB vaccine and its role in preventing transmission and inducing herd immunity | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1080/14760584.2022.2003708 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/GNT1155066 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | McMillan, M. [0000-0002-6490-7707] | - |
dc.identifier.orcid | Marshall, H.S. [0000-0003-2521-5166] | - |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.